Associated Papers
Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets.
Hu Z et al.
Jacs Au, 2026
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.
van Tienen LM et al.
Cell Chemical Biology, 2026
Convergence for Inactivation of TGF-β Signaling Is a Common Feature of Advanced Pancreatic Cancer.
Hong J et al.
Cancer Discovery, 2026
Metabolic permissiveness: how tissue context shapes cancer.
Moschandrea C et al.
Genes & Development, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
The molecular profile of ovarian struma ovarii.
Calejero I et al.
Human Pathology, 2026
Histomorphological and Molecular Features of Colonic Large-Cell Neuroendocrine Carcinoma in a Patient With Familial Adenomatous Polyposis: A Case Report and Review of Literature.
Moustafa M et al.
International Journal of Surgical Pathology, 2026
Synonymous Variants of Potential Significance Identified by a 52-Gene Clinical Sequencing Panel in Non-Small Cell Lung Cancer.
Varty K et al.
Genes, Chromosomes & Cancer, 2026
Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer.
Raji S et al.
Jco Precision Oncology, 2026
Diffuse low-grade glioma with a rare BRAF p.T599dup mutation in a child: importance of clinicopathological and molecular correlation.
Yamada S et al.
Brain Tumor Pathology, 2026
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.
Burge RA et al.
Cancer Research, 2026
Tumor microenvironment changes after treatment with avelumab and immune-stimulating agent combinations in patients with advanced solid tumors.
Lermi NO et al.
Research Square, 2026
Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.
Ochman B et al.
International Journal of Molecular Sciences, 2026
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
Spectrum of KRAS variants in primary lung mucinous adenocarcinoma: implications for diagnosis, testing, and therapy.
Htoo A et al.
Journal of the American Society of Cytopathology, 2026
Six-Color Multiplex Digital PCR Assays for Comprehensive Screening and Identification of Multiple Driver Mutations Associated with Pancreatic Carcinogenesis.
Maeda C et al.
Clinical Chemistry, 2026
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Zaghla BKQ et al.
Journal for Immunotherapy of Cancer, 2026
KRAS mutation and its association with clinicopathological features of colorectal cancer patients in Africa: a systematic review and meta-analysis.
Kassaw AB et al.
Bmc Cancer, 2026
Gene, genetics and genetic medicines in gastroenterology: Current status and its future.
Kumar A et al.
World Journal of Gastroenterology, 2026
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
BRAF p.Val600Glu Mutations Are Not Detected in Adenomatoid Odontogenic Tumors.
Gonçalves J et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2026
FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer.
Ber S et al.
Embo Reports, 2026
Translational Relevance of the Genomic Landscape of KRASG12D-Mutant Colorectal and Pancreatic Cancers.
Jazieh K et al.
Targeted Oncology, 2026
Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.
Hernandez S et al.
Lung Cancer (amsterdam, Netherlands), 2026
The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.
Jentus MM et al.
Pathology International, 2026
Prognostic Significance of SOX9 and Its Combination With RAS and TP53 Mutations Following Colorectal Cancer Liver Metastasectomy.
Duan JL et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2025
Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s).
Wang SA et al.
Haematologica, 2025
Genomic characterization and prognosis of pancreatic adenosquamous carcinoma.
Huang Y et al.
Pancreatology : Official Journal of the International Association of Pancreatology (iap) ... [et Al.], 2025
Liquid Biopsy and Automated Next-Generation Sequencing: Achieving Results in 27 Hours Within a Community Setting.
Yajima T et al.
Diagnostics (basel, Switzerland), 2025
Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Chibaudel B et al.
International Journal of Molecular Sciences, 2025
Genetic diversity in melanomagenesis: a comprehensive analysis of BRAF, NRAS, KIT and novel mutations across melanoma subtypes.
Göze ÖF et al.
Bmc Cancer, 2025
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.
Motta L et al.
Cancers, 2025
Acute promyelocytic leukemia with a rare TBL1XR1::RARA fusion and distinctive morphologic and phenotypic attributes.
Halloran P et al.
Journal of Hematopathology, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Quantitative Reactivity Profiling of Functional Arginine Residues in Human Cancer Cell Line Proteomes.
Zhao W et al.
Angewandte Chemie (international Ed. in English), 2025
Age-Related Multigene Analysis of Colorectal Cancer Using Next-Generation Sequencing.
Kozlowska-Geller M et al.
Cancers, 2025
CDKN2A homozygous deletions and TSC2 somatic mutations in metastatic pancreatic neuroendocrine tumors.
Jesus TT et al.
Npj Precision Oncology, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077).
Song KW et al.
Molecular Cancer Therapeutics, 2025
Renal Tumorigenesis via RAS/RAF/MAPK Pathway Alterations Beyond Papillary Renal Neoplasm With Reverse Polarity.
Kwon JW et al.
The American Journal of Surgical Pathology, 2025
Chemotherapy-associated mutational process signature and genomic alterations associated with outcome in metastatic pancreatic cancer.
Wang K et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025
Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer.
Safyan RA et al.
Surgical Oncology, 2025
Functional validation of somatic variability in TP53 and KRAS for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients.
Mohammad AOA et al.
Cancer Biology & Therapy, 2025
Aspyre Lung enables robust variant calling in samples that fail next generation sequencing quality control.
Gray ER et al.
Translational Oncology, 2025